Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
September 10, 2026 VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting one of pharmaceutical development's most expensive challenges: identifying drug toxicity before a candidate reaches human clinical trials. Using its NAMkind™ 3D human liver and intestinal models combined with AI-powered predictive toxicology, VivoSim is developing tools designed to help pharmaceutical companies determine which drug candidates should advance, be modified or be discontinued earlier .
CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds.
Speaking at an investor conference, Chief Financial Of
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.
